Daratumumab

立即咨询

Daratumumab

本产品不向个人销售，仅用作科学研究，不用于任何人体实验及非科研性质的动物实验。

CAS NO:

945721-28-8

包装与价格：

包装	价格(元)
1mg	电议
5mg	电议
10mg	电议
50mg	电议

产品名称

达雷木单抗
Anti-Human CD38, Human Antibody

产品介绍

Daratumumab (Anti-Human CD38) 是首创的特异性抗CD38单克隆抗体 (IgG1)。Daratumumab 具有抗多发性骨髓瘤(MM) 的作用。Daratumumab 损伤了 MM 细胞的粘附，从而增加了 MM 对蛋白酶体抑制的敏感性。

生物活性

Daratumumab (Anti-Human CD38) is the first-in-class human-specificanti-CD38monoclonal antibody (IgG1). Daratumumab has anti-multiple myeloma (MM) effect. Daratumumab impairs MM cell adhesion, which results in an increased sensitivity of MM toproteasomeinhibition^[1]^[2].

体外研究
(In Vitro)

Daratumumab (Anti-Human CD38) induces potent Ab-dependent cellular cytotoxicity in CD38-expressing lymphoma- and MM-derived cell lines^[2].

体内研究
(In Vivo)

Daratumumab (i.p.; 0.5 mg/kg; 14 d after challenge with Daudi-luc cells) inhibits outgrowth of CD38-expressing tumor cells in mouse xenograft tumor models^[2].

Animal Model:	8- to 10-wk-old C.B-17 SCID mice (luciferase-expressing Daudi cells)^[2]
Dosage:	0.5 mg/kg
Administration:	I.p.; 14 day after challenge with Daudi-luc cells
Result:	Effectively inhibited tumor growth compared with control-treated animals in which tumor grew rapidly and therefore required euthanasia on day 35. On day 28 and day 35, tumor size in Daratumumab-treated animals was significantly different from the control.

Clinical Trial

性状

Liquid

CAS 号

945721-28-8

中文名称

达雷妥尤单抗；达妥木单抗

储存方式

Please store the product under the recommended conditions in the Certificate of Analysis.